Off-label use for direct oral anticoagulants: valvular atrial fibrillation, heart failure, left ventricular thrombus, superficial vein thrombosis, pulmonary hypertension—a …

H Brokmeier, K Kido - Annals of Pharmacotherapy, 2021 - journals.sagepub.com
Objective: To evaluate clinical literature for direct oral anticoagulants (DOACs) therapy for
non–Food and Drug Administration approved indications. Data Sources: Articles from …
被引用次数：16 相关文章

Off-label Use for Direct Oral Anticoagulants: Valvular Atrial Fibrillation, Heart Failure, Left Ventricular Thrombus, Superficial Vein Thrombosis, Pulmonary Hypertension …

H Brokmeier, K Kido - The Annals of Pharmacotherapy, 2020 - europepmc.org
Off-label Use for Direct Oral Anticoagulants: Valvular Atrial Fibrillation, Heart Failure, Left
Ventricular Thrombus, Superficial Vein Thrombosis, Pulmonary Hypertension-a Systematic …
[HTML] nih.gov

[HTML][HTML] Off-label Use for Direct Oral Anticoagulants: Valvular Atrial Fibrillation, Heart Failure, Left Ventricular Thrombus, Superficial Vein Thrombosis, Pulmonary …

H Brokmeier, K Kido - The Annals of pharmacotherapy, 2021 - ncbi.nlm.nih.gov
Objective: To evaluate clinical literature for direct oral anticoagulants (DOACs) therapy for
non–Food and Drug Administration approved indications. Data Sources: Articles from …

Off-label Use for Direct Oral Anticoagulants: Valvular Atrial Fibrillation, Heart Failure, Left Ventricular Thrombus, Superficial Vein Thrombosis, Pulmonary Hypertension …

H Brokmeier, K Kido - The Annals of pharmacotherapy, 2021 - pubmed.ncbi.nlm.nih.gov
Objective To evaluate clinical literature for direct oral anticoagulants (DOACs) therapy for
non-Food and Drug Administration approved indications. Data sources Articles from …